Specialty drug costs strain Central Pennsylvania employer health plans

Not long ago, pharmacy benefits were a relatively predictable line item in an employer’s benefits budget. That’s no longer the case. Specialty drugs, a category that once represented a small fraction of total pharmacy spend, now account for the majority of drug costs for many employer-sponsored health plans. Understanding how that happened, and what it means for employers, is increasingly important context for anyone making benefits decisions today. 

What counts as a specialty drug  

Specialty drugs are medications used to treat complex, chronic, or rare conditions. They include treatments for rheumatoid arthritis, multiple sclerosis, cancer, Crohn’s disease, and a growing list of metabolic and genetic conditions. Many require special handling, administration, or ongoing clinical monitoring. Nearly all carry a high price tag, often exceeding the cost of traditional medications by an order of magnitude.  

The category has expanded significantly over the past decade. Advances in biologics, immunotherapies, and gene therapies have produced treatments that are genuinely transformative for patients with conditions that previously had few options. But the pricing structure that accompanies those breakthroughs has introduced a new layer of financial complexity for the plans that cover them. 

A small slice of volume, a large share of cost  

Specialty drugs represent roughly one to two percent of all prescriptions filled in the United States. Yet for many employer health plans, they account for more than half of total pharmacy spend. The imbalance between utilization volume and overall cost is what makes this category challenging to absorb within traditional plan design structures.  

For fully insured employers, rising specialty drug costs often drive renewal rate increases that appear disconnected from their employees’ actual healthcare utilization. For self funded employers, the exposure is more direct, a single employee on a high-cost specialty medication can shift the entire claims picture for a plan year. Either way, the financial impact is real and growing. 

The pipeline is making it worse  

What’s already happened in specialty pharmacy is significant. What lies ahead may prove even more significant.  

The pipeline of new specialty drugs moving through FDA approval includes a large and expanding class of cell and gene therapies, treatments that, in some cases, offer the potential to address the root cause of a disease rather than manage its symptoms. Several of these therapies carry one-time price tags in the millions of dollars. Others require ongoing administration at costs that far exceed anything in a standard formulary.  

As these treatments move from clinical trials into standard care, employers will increasingly find themselves making coverage decisions about therapies that didn’t exist when their current plan was designed. The actuarial assumptions underlying many employer plans were not built for this environment. 

Why traditional plan design isn’t keeping up  

The structure of most employer-sponsored health plans was built around a pharmaceutical landscape that looks very different from today’s. Standard formulary tiers, copay structures, and pharmacy benefit manager contracts were designed with traditional medications in mind. They don’t translate cleanly to a world where a single prescription can cost more than a year of premiums.  

Many employers don’t have visibility into their specialty drug utilization in a way that allows for meaningful analysis. Aggregate claims data often obscures where specialty spend is concentrated, making it difficult to understand the actual risk profile of the plan. Without that visibility, it’s hard to know whether the current plan design is managing the exposure appropriately or simply hasn’t been tested yet. 

 The pharmacy benefit manager relationship is another layer of complexity. PBM contract structures vary widely, and the financial incentives built into those contracts don’t always align with an employer’s cost containment goals. For specialty drugs, where rebate structures and dispensing arrangements can significantly affect net cost, the details of the PBM relationship matter more than most employers realize. 

A cost driver that’s becoming impossible to ignore  

There was a period when specialty drug costs were largely a concern for large, self funded employers with the scale and resources to monitor and manage them closely.  

That’s no longer true. Mid-size employers across Central Pennsylvania and the country are seeing specialty drug spend show up in their claims data in ways that are affecting renewal conversations, plan sustainability, and total benefits costs.  

The conditions managed with specialty medications are more common than often assumed. Rheumatoid arthritis, inflammatory bowel disease, and cancer affect working age adults across every industry and workforce size. As the treated population grows and the number of available specialty therapies expands, the probability that any given employer plan will carry high-cost specialty claimants increases alongside it.  

Understanding the scope of this cost driver, where it comes from, why it’s accelerating, and what it means for plan sustainability, is the first step toward addressing it. For employers heading into renewal conversations in the months ahead, it’s a topic worth raising with your benefits advisor before the numbers show up on a renewal quote. 

Jamie Hudson, Employee Benefits Executive Consultant at McConkey Insurance & Benefits can be reached at [email protected].  

McConkey Insurance & Benefits has operated independently in York, PA since 1890. Licensed in nearly 50 states and serving clients in more than 20 countries, McConkey is recognized as one of the Mid-Atlantic’s largest and most respected insurance brokerage firms.